Cervical cancer treatment also includes immunotherapy

Share This Post

Immunotherapy has brought promising breakthroughs to several types of cancer. Cervical cancer has a relatively large number of mutations (gene changes), which may make it more sensitive to immunotherapy drugs and may apply immunotherapy to cervical cancer.

A number of clinical trials are in full swing, and the researchers recently summarized a phase II trial of single drug nivolumab (Opdivo) for recurrent cervical cancer. Among the 24 patients: 19 had cervical cancer, 5 had vaginal cancer, and 26% of cervical cancer patients responded to the drug, which is an encouraging result.

Researchers will continue to improve the single-drug program through further trials, but are also pursuing another approach: combination trials. Studies using single-agent immunotherapy with drugs such as pembrolizumab (Keytruda) or nivolumab show that 15% -25% of patients are active, but the remaining patients are inactive, and there is much room for improvement. For this reason, the researchers are more focused on combined trials of cervical cancer.

An experiment is under way to pair the immunotherapy drug atezolizumab (Tecentriq) with the anti-angiogenic agent bevacizumab, which prevents cancer cells from forming new blood vessels that need to grow. Bevacizumab is an active drug against cervical cancer, and there are preclinical data that bevacizumab can improve the efficacy of immunotherapy. Therefore, this is an exciting combination of cervical cancer, and we are eagerly awaiting the results of this study.

In another clinical trial, researchers are studying how two immunotherapy drugs, durvalumab (IMFINZI) and tremelimumab, can be combined with radiation therapy to see if radiation can enhance the immune response.

More and more cervical cancer immunotherapy research has added great hope to cervical cancer patients, and we look forward to better treatment effects.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy